BB 401
Alternative Names: BB-401Latest Information Update: 16 Feb 2021
At a glance
- Originator Benitec Biopharma
- Class Antineoplastics; Antisense oligonucleotides; Antisense RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Head and neck cancer
Most Recent Events
- 30 Jun 2020 Benitec Biopharma terminated an agreement with NantWorks for development of BB 401
- 30 Jun 2020 Discontinued - Phase-I/II for Head and neck cancer in USA (unspecified route)
- 30 Jun 2020 Discontinued - Phase-II for Head and neck cancer (Metastatic disease, Recurrent, Second-line therapy or greater) in Australia (Intratumoural)